Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M

Autolus Therapeutics plc

2025-FY EPS reported -$1.08 vs consensus -$0.27 ▼ miss (-297.6%)

Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.
FY 2026 revenue guidance $120M-$135M; expects positive gross margin in 2026.
Cash runway extended into Q4 2027 based on current operating plans.
Pipeline: obe-cel Phase 2 CATULUS (pediatric B-ALL) and LUMINA (lupus nephritis) enrolling; BOBCAT (MS) and AUTO8 (AL amyloidosis) first patients dosed.
UK commercial launch under NICE approval; manufacturing cost reduction initiatives underway.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.